Primary Biliary Cholangitis Treatment Market - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Primary Biliary Cholangitis Treatment Market - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Primary Biliary Cholangitis (PBC) is a rare disease characterized by chronic progressive liver disorder. It majorly affects women and usually occurs in middle age ranging between 30 to 60 years. It is also called as biliary cirrhosis. PBC tends to affect the small bile duct present in the liver. Primary biliary cholangitis is divided into four stages including stage 1 with no significant scarring to stage 4 known as cirrhosis. PBC is triggered by the combination of factors such as autoimmune, genetic, and environmental factors.
Market Dynamics
Increasing number of Food and Drug Administration (FDA) approvals for the drugs to treat PBC is contributing to the market growth. For instance, in May 2016, the U.S. Food and Drug Administration (FDA) approved Ocaliva (obeticholic acid) in combination with ursodeoxycholic acid (UDCA) for the treatment of Primary Biliary Cholangitis (PBC) in adults with an inadequate response to UDCA. Furthermore, in 2016, Ocaliva was assigned fast track designation and orphan drug designation by the U.S. FDA.
Moreover, in February 2018, U.S.FDA granted orphan drug designation (ODD) to Calliditas Therapeutics AB, specialty pharmaceutical company engaged in development of high quality pharmaceutical products for patients with a significant unmet medical need in niche indications, in Stockholm, Sweden, for the treatment of Primary biliary cholangitis (PBC).
Furthermore, key players are engaged in conducting clinical trial to develop treatment for primary biliary cholangitis. For instance, in February 2021, Zydus Cadila received the US Food and Drug Administration (USFDA) approval to initiate a Phase-2 clinical trial of Saroglitazar Magnesium (Mg) in patients with Primary Biliary Cholangitis of the liver.
Key features of the study:
This report provides in-depth analysis of the primary biliary cholangitis treatment market size (US$ Mn), and cumulative annual growth rate (CAGR (%)) for the forecast period (2022-2028), considering 2021, as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by the leading players
It profiles leading players in the global Primary Biliary Cholangitis Treatment Market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
Key players covered as a part of this study include Novartis AG, Bristol-Myers Squibb, NGM Biopharmaceuticals, Lumena Pharmaceuticals, Inc., TARGET PharmaSolutions, Inc., Intercept Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., Retrophin, Inc., Calliditas Therapeutics AB, and GlaxoSmithKline (GSK) pharmaceuticals.
Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
The global Primary Biliary Cholangitis Treatment Market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors and suppliers for Primary Biliary Cholangitis Treatment Market, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:
Global Primary Biliary Cholangitis Treatment Market, By Treatment Type
Ursodeoxycholic acid (UDCA)
Obeticholic acid (Ocaliva)
Global Primary Biliary Cholangitis Treatment Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Primary Biliary Cholangitis Treatment Market, By Region:
North America
By Country:
U.S.
Canada
By Treatment Type:
Ursodeoxycholic acid (UDCA)
Obeticholic acid (Ocaliva)
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Europe
By Country:
U.K.
Germany
Italy
Spain
France
Russia
Rest of Europe
By Treatment Type:
Ursodeoxycholic acid (UDCA)
Obeticholic acid (Ocaliva)
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Asia Pacific
By Country:
Australia
India
China
Japan
ASEAN
South Korea
Rest of Asia Pacific
By Treatment Type:
Ursodeoxycholic acid (UDCA)
Obeticholic acid (Ocaliva)
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Latin America
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
By Treatment Type:
Ursodeoxycholic acid (UDCA)
Obeticholic acid (Ocaliva)
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Middle East
By Country:
GCC
Israel
Rest of Middle East
By Treatment Type:
Ursodeoxycholic acid (UDCA)
Obeticholic acid (Ocaliva)
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Africa
By Country:
South Africa
Central Africa
North Africa
By Treatment Type:
Ursodeoxycholic acid (UDCA)
Obeticholic acid (Ocaliva)
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Company Profiles
Novartis AG,*
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Bristol-Myers Squibb.
NGM Biopharmaceuticals
Lumena Pharmaceuticals, Inc.
TARGET PharmaSolutions, Inc
Intercept Pharmaceuticals, Inc
Teva Pharmaceutical Industries Ltd
Retrophin, Inc.
Calliditas Therapeutics AB.
GlaxoSmithKline (GSK) pharmaceuticals

“*” marked represents similar segmentation in other categories in the respective section.